1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
POLISH FINANCIAL SUPERVISION AUTHORITY |
|||||||||||
|
UNI - EN REPORT No |
19 | / |
2026 |
|
||||||
Date of issue: |
2026-04-09 |
||||||||||
Short name of the issuer |
|||||||||||
KRKA |
|||||||||||
Subject |
|||||||||||
025 Supervisory Board Report of Krka, d. d., Novo mesto |
|||||||||||
Official market - legal basis |
|||||||||||
Art. 17 ust. 1 MAR |
|||||||||||
Unofficial market - legal basis |
|||||||||||
Contents of the report: |
|||||||||||
Based on the provisions of the Rules of the Ljubljana Stock Exchange, d. d., Ljubljana and Article 134 of the Market in Financial Instruments Act, Krka, d. d., Novo mesto publishes the 2025 Supervisory Board Report of Krka, d. d., Novo mesto. The report will be published on the Company's website (www.krka.biz) from 9 April 2026 onwards, for a period of at least 10 years. |
|||||||||||
Annexes |
|||||||||||
File |
Description |
||||||||||
2025 Supervisory Board Report of Krka, d. d., Novo mesto.pdf |
2025 Supervisory Board Report of Krka Novo mesto |
||||||||||
KRKA, TOVARNA ZDRAVIL D.D. |
|||||||||||||
(fullname of the issuer) |
|||||||||||||
KRKA |
Farmaceutyczny (far) |
||||||||||||
(short name of the issuer) |
(sector according to clasification of the WSE in Warsow) |
||||||||||||
8501 |
Nove Mesto |
||||||||||||
(post code) |
(city) |
||||||||||||
Smarjeska |
6 | ||||||||||||
(street) |
(number) |
||||||||||||
+386 7 331 21 11 |
+386 7 332 15 37 |
||||||||||||
(phone number) |
(fax) |
||||||||||||
(e-mail) |
(web site) |
||||||||||||
nie dotyczy |
|||||||||||||
(NIP) |
(REGON) |
||||||||||||
SIGNATURE OF PERSONS REPRESENTING THE COMPANY |
|||||
Date |
Name |
Position / Function |
Signature |
||
2026-04-09 |
Jože Colarič |
President of the Management Board and CEO |
|||
